HopeStage
Back to overview

Schizophrenia studies

Topics
More filters

Schizophrenia

Schizophrenia can affect how a person perceives reality, thinks and feels, sometimes involving hearing voices or holding unusual beliefs.

4505studies shown
Showing 1,117-1,128 of 4,505
Drug study icon
CompletedNCT04531982

Pimavanserin for schizophrenia

What is this study about?

This study evaluated the safety and effectiveness of Pimavanserin for people with schizophrenia.

This study has finished and is no longer accepting participants.

Multiple locations, including Buenos Aires
SchizophreniaMedication studyAges 18–55
Countries
Argentina, Bulgaria, Croatia, + 9 others
Sponsor
ACADIA Pharmaceuticals Inc.
Device study icon
UnknownNCT06494124

TACS vs tDCS for schizophrenia

Official study title

Comparison of Efficacy and Safety of Transcranial Alternating Current Stimulation vs Transcranial Direct Current Stimulation on Psychopathology Measures and Neurocognition in Chronic Schizophrenia: A Randomized Double-blind Controlled Trial

Current recruitment status is unconfirmed.

In Bhubaneswar
SchizophreniaDevice studyAges 18–60
Countries
India
Sponsor
All India Institute of Medical Sciences, Bhubaneswar
Drug study icon
CompletedNCT00202007

Efficacy and Safety Study of Aripiprazole to Treat Schizophrenia

Official study title

A Multi-Center, Randomized, Double-Blind Study, Comparing With Risperidone, to Evaluate the Efficacy and Safety of Aripiprazole in the Treatment of Patients With Schizophrenia

This study has finished and is no longer accepting participants.

Multiple locations, including Guangzhou
SchizophreniaMedication studyAges 18–65
Countries
China
Sponsor
Otsuka Beijing Research Institute
Behavioral study icon
CompletedNCT02678858

Efficacy of ISST in Schizophrenia

Official study title

Efficacy of "Integrated Social Cognitive and Behavioral Skills Therapy" (ISST) in Improving Functional Outcome in Schizophrenia

This study has finished and is no longer accepting participants.

Multiple locations, including Alzey
SchizophreniaBehavioural studyAges 18–65
Countries
Germany
Sponsor
Heinrich-Heine University, Duesseldorf
Device study icon
CompletedNCT05282329

Efficacy of tACS for Treatment of Auditory Hallucinations in Refractory Schizophrenia

Official study title

Efficacy of Transcranial Alternating Current Stimulation (tACS) as an Add-on Treatment for Auditory Hallucinations in Refractory Schizophrenia: A Randomized, Double-blind, Sham-controlled Trial

This study has finished and is no longer accepting participants.

In Tianjin
SchizophreniaDevice studyAges 18–70
Countries
China
Sponsor
Tianjin Anding Hospital
Behavioral study icon
CompletedNCT05130853

Efficacy Study of a New Individualized Rehabilitation Programme for Social Cognition in people with Schizophrenia

Official study title

Social Cognition Individualized Activities Lab (SoCIAL) for the Training of Social Cognition and Narrative Enhancement in Patients With Schizophrenia: A Randomized Controlled Study to Assess Efficacy and Generalization to Real-life Functioning

This study has finished and is no longer accepting participants.

In Naples
SchizophreniaBehavioural studyAges 18–50
Countries
Italy
Sponsor
University of Campania Luigi Vanvitelli
Drug study icon
CompletedNCT05278156

Efficacy, Safety and Pharmacokinetics Study of CPL500036 (PDE10A Inhibitor) in people with Schizophrenia

Official study title

Phase II, Double Blind, Randomized, Placebo Controlled, Parallel Group, Trial to Explore Efficacy, Safety and Pharmacokinetics of CPL500036 (PDE10A Inhibitor) in Patients With an Acute Exacerbation of Schizophrenia

This study has finished and is no longer accepting participants.

Multiple locations, including Budapest
SchizophreniaMedication studyAges 18–65
Countries
Hungary, Poland, Ukraine
Sponsor
Celon Pharma SA
Drug study icon
TerminatedNCT03896945

Efficacy, Safety, and Tolerability of AVP-786 for Negative Symptoms of Schizophrenia

What is this study about?

Researchers are comparing AVP-786 and placebo to find out how the approaches affect psychotic symptoms in people with schizophrenia.

This study ended early.

Multiple locations, including Little Rock
SchizophreniaMedication studyAges 18–60
Countries
United States, Bulgaria, Poland
Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc. (Pharmaceutical company)
Drug study icon
CompletedNCT05545111

Safety study of NBI-1117568 in schizophrenia

What is this study about?

This study evaluated the safety and effectiveness of NBI-1117568 for people with schizophrenia.

This study has finished and is no longer accepting participants.

Multiple locations, including Little Rock
SchizophreniaMedication studyAges 18–55
Countries
United States
Sponsor
Neurocrine Biosciences (Biotech company)

Registry coverage

We gather information about mental health clinical trials from the public registries we index. Coverage is still expanding, so some studies may not appear yet.